<DOC>
	<DOC>NCT02521610</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, ascending-dose, parallel-group study will evaluate the pharmacodynamic effects, pharmacokinetics, safety, and tolerability of one week of RG7625 dosing in healthy male and female volunteers. Each participant will receive a single dose of RG7625 or placebo followed by one week of dosing with the same treatment. Each participant will also receive intradermal administration of 4 recall antigens at Screening and on Day 7 of treatment to assess study drug effects on delayed-type hypersensitivity (DTH).</brief_summary>
	<brief_title>A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy adult males and females 18 to 60 years of age, inclusive Body mass index 18.0 to 30.0 kilograms per metersquared (kg/m^2), inclusive Any clinically relevant abnormalities, concomitant diseases or ongoing medical conditions, abnormal laboratory test results, or a history of any other clinically significant disorders Any major illness within the one month preceding the Screening visit, or any febrile illness within the two weeks preceding the Screening visit Any significant allergic reaction to drugs Immunocompromised or with reduced immune function and/or immunization within 30 days before the first study drug administration or planning vaccination during the study Women who are pregnant or lactating or of childbearing potential Clinically significant abnormal electrocardiogram (ECG) or other risk factors for QT prolongation Use of prescribed or overthecounter medication Inability or unwillingness to comply with study requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>